0000000000639937

AUTHOR

Xavier Freixa

showing 6 related works from this author

Prognostic role of tapse to pasp ratio in patients undergoing mitraclip procedure

2021

Producción Científica

medicine.medical_specialtyTransthoracic echocardiographyCorazón - Cirugíamedicine.medical_treatmentCardiology3205.01 Cardiologíalcsh:MedicineHeart valves - Diseases - diagnostic imaging030204 cardiovascular system & hematologyRight ventricular to pulmonary arterial couplingArticlePulmonary hypertension03 medical and health sciencesmitral valve repairtransthoracic echocardiography0302 clinical medicineInternal medicinepulmonary hypertensionmedicineMitraClipCorazón - Enfermedades030212 general & internal medicineMitral valve repairMitral regurgitationMitral valve - Diseases - ImagingProportional hazards modelbusiness.industryMitraClipmitral valve regurgitationlcsh:RGeneral MedicineCardiac surgerymedicine.disease3207.04 Patología CardiovascularPulmonary hypertensionHipertensión pulmonarBlood pressureEchocardiographyHeart failureCardiologyright ventricular to pulmonary arterial couplingHeart - DiseasesMitral valve regurgitationbusinessMitral valve repairMitral valve regurgitation
researchProduct

Clinical and echocardiographic outcomes of transcatheter mitral valve repair in atrial functional mitral regurgitation.

2021

Background: Isolated atrial fibrillation can cause mitral regurgitation (MR) in patients with normal left ventricular systolic function and no organic disease of the mitral valve. Little information is available regarding outcomes of Mitraclip in patients with atrial functional mitral regurgitation (AFMR). We aimed to evaluate 12-month clinical and echocardiographic outcomes of transcatheter mitral valve repair (TMVR) with MitraClip in patients with AFMR compared to those with ventricular functional or degenerative/mixed MR. Methods: Registry-based analysis of all consecutive patients who underwent TMVR and were included in the Spanish Registry of Mitraclip. Changes in MR and NYHA functiona…

MaleAtrial mitral regurgitation Functional mitral regurgitation MitraClipmedicine.medical_specialtyCardiac CatheterizationOrganic diseaseInternal medicineMitral valvemedicineMitraClipHumansHeart Atriacardiovascular diseasesAtrial mitral regurgitationFunctional mitral regurgitationAgedAged 80 and overHeart Valve Prosthesis ImplantationMitral regurgitationbusiness.industryMitraClipMitral Valve InsufficiencyAtrial fibrillationMiddle Agedmedicine.diseasemedicine.anatomical_structureTreatment OutcomeFunctional mitral regurgitationEchocardiographyHeart failureCardiologycardiovascular systemMitral ValveTranscatheter mitral valve repairFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Comparison of One-Year Outcomes Between the ihtDEStiny BD Stent and the Durable-Polymer Everolimus- and Zotarolimus-Eluting Stents: A Propensity-Scor…

2021

Abstract Objectives We sought to evaluate clinical outcomes in patients treated with the drug-eluting stent ihtDEStiny BD. Background The ihtDEStiny BD stent is a metallic sirolimus eluting stent with a biodegradable polymer with both drug and polymer coating the abluminal surface of the stent and balloon. Methods In this study, the clinical outcomes of a multicenter prospective registry of patients treated with this stent (DEStiny group) were analyzed and compared with those of a control group of patients treated with durable polymer everolimus or zotarolimus eluting stents (CONTROL group) paired by propensity score matching . Primary outcome was the target vessel failure (TVF) at 12 month…

medicine.medical_specialtyPolymersmedicine.medical_treatment030204 cardiovascular system & hematologyProsthesis DesignCoronary artery disease03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionAbsorbable ImplantsmedicineClinical endpointHumansZotarolimus030212 general & internal medicineMyocardial infarctionEverolimusPropensity ScoreSirolimusEverolimusbusiness.industryStentDrug-Eluting StentsGeneral Medicinemedicine.diseaseSurgeryTreatment OutcomeDrug-eluting stentPropensity score matchingCardiology and Cardiovascular Medicinebusinessmedicine.drugCardiovascular revascularization medicine : including molecular interventions
researchProduct

Transcatheter Mitral Repair for Functional Mitral Regurgitation According to Left Ventricular Function: A Real-Life Propensity-Score Matched Study

2020

Background: Transcatheter mitral valve repair (TMVR) could improve survival in functional mitral regurgitation (FMR), but it is necessary to consider the influence of left ventricular ejection fraction (LVEF). Therefore, we compare the outcomes after TMVR with Mitraclip&reg

medicine.medical_specialtylcsh:Medicine030204 cardiovascular system & hematologyMitraclipArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineIn patient030212 general & internal medicinecardiovascular diseasesFunctional mitral regurgitationEjection fractionVentricular functionbusiness.industryMitraCliplcsh:RGeneral Medicinetranscatheterleft ventricular ejection FractionPropensity score matchingCardiologycardiovascular systemObservational studyTranscatheter mitral valve repairbusinesscirculatory and respiratory physiologyfunctional mitral regurgitationJournal of Clinical Medicine
researchProduct

Acute Kidney Injury After Percutaneous Edge-to-Edge Mitral Repair.

2020

BACKGROUND In catheter-based procedures, acute kidney injury (AKI) is a frequent, serious complication ranging from 10% to 30%. In MitraClip (Abbott Vascular, Santa Clara, California), a usually contrast-free procedure, there is scarce data about its real incidence and impact. OBJECTIVES This study aimed to evaluate incidence, predictive factors, and midterm outcomes of AKI in patients with significant mitral regurgitation (MR) undergoing transcatheter valve repair with MitraClip. METHODS A total of 721 patients undergoing MitraClip were included. AKI was defined as an absolute or a relative increase in serum creatinine of >0.3 mg/dl or >= 50%, respectively, or the need for hemodialysis dur…

Malemedicine.medical_specialtyMitral Valve Annuloplastymedicine.medical_treatmentPopulationRenal function030204 cardiovascular system & hematologyoutcomesurologic and male genital diseasesrenal insufficiency03 medical and health sciences0302 clinical medicinePostoperative ComplicationsInterquartile rangeInternal medicinemedicineMitraClipHumans030212 general & internal medicinemitral edge-to-edge repaireducationAgedRetrospective StudiesAged 80 and overMitral regurgitationeducation.field_of_studybusiness.industryMitraClipIncidenceEndovascular ProceduresAcute kidney injuryMitral Valve InsufficiencyAcute Kidney InjuryMiddle AgedMitraClip acute kidney injury mitral edge-to-edge repair mortality outcomes renal insufficiencymedicine.diseasemortalityfemale genital diseases and pregnancy complicationsacute kidney injurySpainCardiologyFemaleHemodialysisCardiology and Cardiovascular MedicineComplicationbusiness
researchProduct

Mobilization of endothelial progenitor cells in acute cardiovascular events in the PROCELL study: Time-course after acute myocardial infarction and s…

2015

The mobilization pattern and functionality of endothelial progenitor cells after an acute ischemic event remain largely unknown. The aim of our study was to characterize and compare the short- and long-term mobilization of endothelial progenitor cells and circulating endothelial cells after acute myocardial infarction or atherothrombotic stroke, and to determine the relationship between these cell counts and plasma concentrations of vascular cell adhesion molecule (VCAM-1) and Von Willebrand factor (VWF) as surrogate markers of endothelial damage and inflammation. In addition, we assessed whether endothelial progenitor cells behave like functional endothelial cells. We included 150 patients…

AdultMaleVascular Endothelial Growth Factor ACD31medicine.medical_specialtyTime FactorsMyocardial InfarctionCD34Vascular Cell Adhesion Molecule-1Cell CountInflammationSeverity of Illness IndexEndothelial progenitor cellImmunophenotypingchemistry.chemical_compoundVasculogenesisRisk FactorsInternal medicinevon Willebrand FactormedicineHumansProspective StudiesProgenitor cellMolecular BiologyCells CulturedAgedEndothelial Progenitor Cellsbusiness.industryEndothelial CellsMiddle AgedStrokeVascular endothelial growth factorPhenotypeEndocrinologychemistryCase-Control StudiesCardiologyCD146Femalemedicine.symptomCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesJournal of Molecular and Cellular Cardiology
researchProduct